Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial

Circulation. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898.

¹ Division of Cardiac Surgery (S.V.) VermaSu@smh.ca.
² St. Michael's Hospital, and Departments of Surgery and Pharmacology and Toxicology (S.V.).
³ Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
⁴ Institute of Life Science, Swansea University, United Kingdom (S.C.B.).
⁵ University of North Carolina School of Medicine, Chapel Hill (J.B.B.).
⁶ Friedrich Alexander University of Erlangen, Germany (J.F.E.M.).
⁷ HCA Midwest Health Heart and Vascular Institute, Kansas City, MO (S.P.M.).
⁸ Diabetes Center Bochum-Hattingen, St. Josef-Hospital, Ruhr-University Bochum, Germany (M.A.N.).
⁹ Faculty of Medicine, National Heart & Lung Institute, Imperial College London, United Kingdom (N.R.P.).
¹⁰ Florida Hospital Translational Research Institute for Metabolism and Diabetes, Orlando, FL (R.E.P.).
¹¹ Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Canada (B.Z.).
¹² Novo Nordisk A/S, Søborg, Denmark (M.M.M., T.M.F., S.R.).
¹³ Li Ka Shing Knowledge Institute (L.A.L.).
¹⁴ University of Toronto (L.A.L.), Canada.

No abstract available

Keywords: atherosclerosis; diabetes mellitus, type 2; glucagon-like peptide 1; liraglutide; myocardial infarction.

Publication types